CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date. dstein Typed or Printed Name Date Signature Feb 28, 2001 IRVN-007CIP2 Attorney Docket Gatanaga et al. First Named Inventor **INFORMATION** 09/700,354 Application Number DISCLOSURE STATEMENT November 13, 2000 Filing Date Unassigned Address to: Group Art Unit Commissioner for Patents Unassigned xaminer Name Washington, D.C. 20231 Factors Affecting Tumor Necrosis itle Factor Receptor Releasing Enzyme Activity.

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date:

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\FORMS\Word 2K forms\IDS - before 1st OA.doc

By:

Carol L. Francis

Registration No. 96,513

Comm	issioner for Patents, Washin	gton, D.C. 2023	1			
Typed	or Printed Name	Steven	F. Gol	dstein		·
Signat	ure	the	oll 7	edst	Date	Feb 28, 2001
				Attorney Docket	IRV	N-007CIP2
				First Named Inventor	Gata	naga et al.
	TRANSMIT		Application Number	09/70	09/700,354	
(to be used for all correspondence after initial filing)			nitial filing)			ember 13, 2000
	/ ~	~~ \(\frac{\chi}{c}\)		-	Unas	ssigned
	MAR 0	6 SOUL ON		Group Art Unit	Una	ssigned
	· \ E			Examiner Name Title: Factors Affectin		Necrosis Factor Receptor
TRADERALIN			Releasing Enzyme Activity.			
ENC	CLOSURES (che		apply)			
	Fee Transmittal For	m	—	e Fee Transmittal h copy of PTOL-85B)	_	Request for Refund
	Amendment/Respon		,	nal Drawing(s)	-	After Allowance Communication to Group
_	Extension of Time I	, .		ensing-related Papers		Appeal Communication to Boar of Appeals and Interferences
	Express Abandonm	ent Request	Acco	tion Routing Slip and impanying Petition	-	Appeal Communication to Group
<u>X</u>	Information Disclos Statement, 1449 and references		· —	onvert a Provisional ication		(Appeal Notice, Brief, Reply Brief)
· —	Certified Copy of P	riority	Pow	er of Attorney Revocation	-	Proprietary Information
	Document(s)		_	Associate		Status Letter
	Response to Missin Incomplete Applica	tion	Cha	nge of Correspondence ess	<u>X</u>	(please identify below):
_	Response to Missi under 37 CFR 1.52 (with copy of Notice	or 1.53	Terr	ninal Disclaimer		Return Postcard
	Missing Parts)	e io i ile	Sma	all Entity Statement		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Individual Name	Carol L. Francis	Registration No.	36,513					
Firm Name	BOZICEVIC, FIELD & FRANCIS ILP							
Signature	Carl & MUST							
Date	relinant 28 text							

F:\FORMS\WORD 2K FORMS\TPANSMITTALS\TRANSMITTAL-GENERIC.DOC